Stock 0A87 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Takeda Pharmaceutical Company Limited London S.E.

Equities

0A87

US8740602052

Market Closed - London S.E.
Other stock markets
 11:28:45 2024-06-18 EDT 		5-day change 1st Jan Change
12.74 USD -2.52% Intraday chart for Takeda Pharmaceutical Company Limited +0.75% -10.44%
06-25 US CDC alerts healthcare providers of increase in dengue cases RE
06-25 Takeda's Cancer Drug Gets European Commission Approval MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US CDC alerts healthcare providers of increase in dengue cases
RE
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
CI
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
MT
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
CI
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
MT
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
RE
Sun Pharma Signs Deal with Japan's Takeda to Commercialize Vonoprazan in India
MT
Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Introducing Novel Gastrointestinal Drug, Voltapraz in India
CI
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP
MT
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting
CI
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback
DJ
Sector Update: Health Care Stocks Decline Premarket Monday
MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall
MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints
MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies
DJ
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome
CI
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. 0A87 Stock
  5. News Takeda Pharmaceutical Company Limited
  6. Highlights